Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
In a double-blind study, 49 geriatric patients suffering from primary major depression were treated with maprotiline or doxepin. Efficacy and safety were assessed by the Hamilton Depression Rating Scale and the Zung Self-Rating Depression and Anxiety scales, side effects profile, routine laboratory tests, and measurements of blood levels. Although marked improvement was obtained with both antidepressants, patients on maprotiline showed statistically greater improvement than those on doxepin. No significant differences were detected between the two drugs with respect to side effects. A significant positive correlation was obtained between dosage and blood levels of maprotiline and doxepin, but there was no correlation between blood levels and clinical response. Overall, results suggest that maprotiline may be superior to doxepin in the treatment of geriatric depression.
D000873:Anthracenes / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D004316:Doxepin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales; D012894:Sleep Stages; D014987:Xerostomia / Q000139:chemically induced
D000873:Anthracenes; D004316:Doxepin; D008376:Maprotiline